Drugs / BSAM2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00889616 | Apr 2009 → Jul 2012 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BSAM2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00889616 ↗ |
| Known as | BSAM-2/Alhydrogel | “Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine” NCT00889616 ↗ |
| Modality | Vaccine | “the blood stage malaria vaccine BSAM2/Alhydrogel®+ CPG 7909” PMID 23056238 ↗ Oct 2012 |
| Route | Intramuscular | “administered in the deltoid muscle” NCT00889616 ↗ |